Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.

New Opioid Speeds Up Recovery Without Increasing Pain Sensitivity or Risk of Chronic Pain

A novel opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System is as strong as morphine but isn't addictive and causes fewer side effects, according to a new study published in the Journal of Neuroinflammation

Continue reading

Oregon Panel Drops Effort to Cut Opioids and Cover Chronic Pain

An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue pr...
Continue reading

Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting Report

The Evidence-based Practice Center (EPC) Program at the Agency for Healthcare Research and Quality (AHRQ) has posted the draft report for the systematic review on Comparative Effectiveness of Analgesics to Reduce Acute P...
Continue reading
Topics:

Patient-Centered Care Is Key to Best Practices in Pain Management

Vanila M. Singh, MD MACM, Chairperson of the HHS Pain Management Inter-Agency Task Force, is interviewed about the task force's recommendations for treating acute and chronic pain. Full story.
Topics:
HHS

Oregon Panel Drops Effort to Cut Opioids and Cover Chronic Pain

An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue prescription opioids. 

Continue reading

AAMC Statement on House Bill to Support New Residency Positions, Including for Pain Management

Association of American Medical Colleges President and CEO Darrell G. Kirch, MD, issued a statement about the Opioid Workforce Act of 2019 (H.R. 2439), which was introduced in the U.S. House of Representatives and would support new addiction medicine, addiction psychiatry, or pain management residency positions. 

Continue reading

FDA Announces Public Meeting to Discuss Safety and Utility of Higher-Dose Opioid Analgesics

FDA is seeking public input on the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient set...
Continue reading
Topics:

FDA MedWatch Safety Alert: Ketorolac Tromethamine Injection by Sagent Pharmaceuticals: Recall - Due to Lack of Sterility Assurance

Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.  

Continue reading

CDC Addresses Concerns Raised in AAPM Foundation Consensus Panel Report on the Challenges of Implementing the CDC Guideline

Earlier this year, a consensus panel report addressing the challenges of implementing the CDC Guideline for Prescribing Opioids for Chronic Pain was published in Pain Medicine . The report, authored by a multidisciplinar...
Continue reading

FDA MedWatch Safety Alert: Fentanyl Transdermal System by Alvogen - Recall: Due to Product Mislabeling

 Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h Fentanyl Transdermal System patches contained 50 mcg/h patches. The 50 mcg/h patches that were included in cartons labeled 12 mcg/h are individually labeled as 50 mcg/h.
Continue reading